KLRC1 and neoplasm: By concurrently targeting NKG2A [13,42] and the well-established modulator CTLA-4 [43,44] in T cell responses, our aptamer seeks to augment the anti-tumor immune response, presenting a comprehensive approach to dual immune checkpoint blockade.